Show simple item record

dc.contributor.authorDu, Zimingen_US
dc.contributor.authorAbedalthagafi, Malaken_US
dc.contributor.authorAizer, Ayal A.en_US
dc.contributor.authorMcHenry, Allison R.en_US
dc.contributor.authorSun, Heather H.en_US
dc.contributor.authorBray, Mark-Anthonyen_US
dc.contributor.authorViramontes, Omaren_US
dc.contributor.authorMachaidze, Revazen_US
dc.contributor.authorBrastianos, Priscilla K.en_US
dc.contributor.authorReardon, David A.en_US
dc.contributor.authorDunn, Ian F.en_US
dc.contributor.authorFreeman, Gordon J.en_US
dc.contributor.authorLigon, Keith L.en_US
dc.contributor.authorCarpenter, Anne E.en_US
dc.contributor.authorAlexander, Brian M.en_US
dc.contributor.authorAgar, Nathalie Y.en_US
dc.contributor.authorRodig, Scott J.en_US
dc.contributor.authorBradshaw, Elizabeth M.en_US
dc.contributor.authorSantagata, Sandroen_US
dc.date.accessioned2015-07-13T18:46:49Z
dc.date.issued2015en_US
dc.identifier.citationDu, Z., M. Abedalthagafi, A. A. Aizer, A. R. McHenry, H. H. Sun, M. Bray, O. Viramontes, et al. 2015. “Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.” Oncotarget 6 (7): 4704-4716.en
dc.identifier.issn1949-2553en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:17295615
dc.description.abstractThere are no effective medical treatments for WHO grade III (anaplastic) meningioma. Patients with this high-grade malignancy have a median survival of less than two years. Therapeutics that modulate the mechanisms that inhibit local immune responses in the tumor microenvironment are showing significant and durable clinical responses in patients with treatment refractory high-grade tumors. We examined the immune infiltrate of 291 meningiomas including WHO grade I-III meningiomas using immunohistochemistry and we examined the expression of PD-L1 mRNA by RNAscope in situ hybridization and PD-L1 protein by immunohistochemistry. In meningioma, the tumor infiltrating lymphocytes are predominantly T cells. In anaplastic meningioma, there is a sharp decrease in the number of T cells, including the numbers of CD4+ and CD8+ T cells and cells expressing PD-1 and there is also an increase in the number of FOXP3 expressing immunoregulatory (Treg) cells. PD-L1 expression is increased in anaplastic meningioma – both mRNA and protein. Using patient derived meningioma cell, we confirm that PD-L1 is expressed in meningioma cells themselves, and not solely in infiltrating immune cells. This work indicates that high-grade meningioma harbor an immunosuppressive tumor microenviroment and that increased Treg cells and elevated PD-L1 may contribute to the aggressive phenotype of these tumors.en
dc.language.isoen_USen
dc.publisherImpact Journals LLCen
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467109/pdf/en
dash.licenseLAAen_US
dc.subjectmeningiomaen
dc.subjectPD-L1en
dc.subjectRNAscopeen
dc.subjectimmunotherapyen
dc.titleIncreased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningiomaen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalOncotargeten
dash.depositing.authorAbedalthagafi, Malaken_US
dc.date.available2015-07-13T18:46:49Z
dash.authorsorderedfalse
dash.contributor.affiliatedAbedalthagafi, Malak
dash.contributor.affiliatedBrastianos, Priscilla
dash.contributor.affiliatedRodig, Scott
dash.contributor.affiliatedBradshaw, Elizabeth M.
dash.contributor.affiliatedFreeman, Gordon
dash.contributor.affiliatedAlexander, Brian
dash.contributor.affiliatedSantagata, Sandro
dash.contributor.affiliatedLigon, Keith
dash.contributor.affiliatedReardon, David
dash.contributor.affiliatedDunn, Ian


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record